Loading…
Coherus Oncology, Inc. is projected to rise to $1.62 by 2027, a +15% move from its current price of $1.41. CHRS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.37 | $1.41 | $1.45 | +0.03% |
| Aug 4 | $1.36 | $1.41 | $1.47 | +0.07% |
| Aug 5 | $1.35 | $1.41 | $1.48 | +0.10% |
| Aug 6 | $1.34 | $1.41 | $1.49 | +0.14% |
| Aug 7 | $1.33 | $1.41 | $1.50 | +0.17% |
| Aug 8 | $1.32 | $1.41 | $1.51 | +0.21% |
| Aug 9 | $1.31 | $1.41 | $1.52 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.31 | $1.41 | $1.52 | +0.24% |
| Week 2 | $1.28 | $1.42 | $1.57 | +0.48% |
| Week 3 | $1.25 | $1.42 | $1.61 | +0.73% |
| Week 4 | $1.23 | $1.42 | $1.65 | +0.97% |
| Week 5 | $1.21 | $1.43 | $1.68 | +1.22% |
| Week 6 | $1.20 | $1.43 | $1.71 | +1.46% |
| Week 7 | $1.18 | $1.43 | $1.74 | +1.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Coherus Oncology, Inc. is a biopharmaceutical company that researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor expressed on Treg cells in the tumor microenvironment.
It has collaboration agreements with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients.
The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
CHRS is the stock name for Coherus Oncology, Inc., currently priced at $1.39 per share. Its market capitalization stands at $214.41M, and it ranks 3692 by market value.
The 2026–2050 forecast shows a path from near-term neutrality to longer-term bullish momentum. In 2026 the min is $1.36, the avg is $1.39, and the max is $1.88, with a neutral sentiment. By 2030, the avg rises to $1.77, and by 2050 the avg is $6.39 with a max of $12.50, reflecting a bullish long-run trajectory.
Forecasted returns evolve from a near-term flat start to substantial upside, with ROI rising from 0 in 2026 to 27.3 in 2030 and 359.8 by 2050.
A major floor 14.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.4% away) — a key level to hold.
The nearest ceiling, 18.4% above — a clean break opens room to run.
A major ceiling 41.1% above — clearing it would confirm fresh momentum.
Key CHRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CHRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.44 | Sell | $1.43 | Sell |
| MA 10 | $1.43 | Sell | $1.44 | Sell |
| MA 20 | $1.48 | Sell | $1.45 | Sell |
| MA 50 | $1.48 | Sell | $1.50 | Sell |
| MA 100 | $1.60 | Sell | $1.55 | Sell |
| MA 200 | $1.60 | Sell | $1.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.86 | Neutral |
| Stoch RSI (14) | 44.19 | Neutral |
| CCI (20) | -67.92 | Neutral |
| Williams %R (14) | -75.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -2.08 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 25.00 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 45.24 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 1.44 | Sell |
| ADX (14) | 10.58 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bearish, with RSI14 at 40. The 50-day simple moving average sits at $1.54 and the 200-day simple moving average at $1.61.
Support is at $1.36 and resistance at $1.67. The 30-day price range spans from $1.13 to $1.71.
Annualized volatility is 60%, highlighting the elevated risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.41 | $1.84 | 0% | Neutral | |
| $1.29 | $1.62 | $2.15 | +15% | Neutral | |
| $1.27 | $1.64 | $2.26 | +16% | Neutral | |
| $1.22 | $1.62 | $2.30 | +15% | Neutral | |
| $1.43 | $1.93 | $2.82 | +37% | Bullish | |
| $1.57 | $2.16 | $3.22 | +53% | Bullish | |
| $1.73 | $2.43 | $3.69 | +72% | Bullish | |
| $1.97 | $2.81 | $4.34 | +99% | Bullish | |
| $1.93 | $2.79 | $4.38 | +98% | Bullish | |
| $1.96 | $2.88 | $4.59 | +104% | Bullish | |
| $2.74 | $4.31 | $7.32 | +206% | Bullish | |
| $4.14 | $7.33 | $13.61 | +420% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.36 | $1.41 | $1.66 | +0.00% |
| September 2026 | $1.20 | $1.42 | $1.73 | +0.81% |
| October 2026 | $1.22 | $1.46 | $1.79 | +2.37% |
| November 2026 | $1.20 | $1.44 | $1.79 | -0.81% |
| December 2026 | $1.22 | $1.47 | $1.84 | +1.95% |
Click any year to see its month-by-month CHRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CHRS could reach as high as $1.84, with a base case around $1.41 and support toward $1.36 — roughly 0% from $1.41. A consolidation phase looks the most probable path here.
Expect CHRS to range from $1.29 to $2.15 through 2027. The $1.62 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
The CHRS price prediction for 2028 points to an average of $1.64 (low $1.27, high $2.26) — a potential gain of +16% on today's $1.41. A consolidation phase looks the most probable path here.
In 2029, CHRS is projected to trade between $1.22 and $2.30, averaging $1.62 — a potential gain of +15% from today's $1.41. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
Coherus Oncology, Inc.'s 2030 outlook centres on $1.93, within a $1.43 to $2.82 range. That is up +19% on the projected 2029 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CHRS could reach as high as $3.22, with a base case around $2.16 and support toward $1.57 — roughly +53% from $1.41. Momentum favours further upside here.
Expect CHRS to range from $1.73 to $3.69 through 2032. The $2.43 average target implies a +72% move from current prices. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CHRS price prediction for 2033 points to an average of $2.81 (low $1.97, high $4.34) — a potential gain of +99% on today's $1.41. Momentum favours further upside here.
In 2034, CHRS is projected to trade between $1.93 and $4.38, averaging $2.79 — a potential gain of +98% from today's $1.41. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Coherus Oncology, Inc.'s 2035 outlook centres on $2.88, within a $1.96 to $4.59 range. That is up +3% on the projected 2034 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2040, CHRS could reach as high as $7.32, with a base case around $4.31 and support toward $2.74 — roughly +206% from $1.41. Buyers look set to stay in control over this stretch.
Expect CHRS to range from $4.14 to $13.61 through 2050. The $7.33 average target implies a +420% move from current prices. That is up +70% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CHRS today (≈ 709.219858 CHRS) could be worth
$5,195.41
+$4,195.41 (+420%) by 2050 · US Dollar
Based on the average projected CHRS price of $7.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CHRSwould be worth at today's price.
$1,000 invested in CHRS on Jul 31, 2025 (≈ 1,063.82979 CHRS) would be worth
$1,500
+$500 (+50.0%) today · 1.50× · US Dollar
Based on a CHRS entry price of $0.94 vs. today's $1.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.41 | $1,000 | +0.0% |
| 1 month ago | $1.44 | $979.17 | -2.1% |
| 3 months ago | $1.8 | $783.33 | -21.7% |
| 6 months ago | $2.17 | $649.77 | -35.0% |
| 1 year ago | $0.94 | $1,500 | +50.0% |
| All time (5.0y) ago | $13.21 | $106.74 | -89.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CHRS forecast.
Our base-case forecast reaches $2.80 around 2033.
Implied market cap at $2.80: $431.9M
Looking over the multi-year horizon, the 2026–2029 period is neutral in sentiment. 2026 shows min $1.36, avg $1.39, max $1.88 (ROI 0). 2027 shows min $1.21, avg $1.55, max $2.09 (ROI 11.3). 2028 shows min $1.16, avg $1.53, max $2.16 (ROI 10.1). 2029 shows min $1.14, avg $1.54, max $2.24 (ROI 10.5).
From 2030 onward the forecast switches to bullish sentiment. 2030: min $1.28, avg $1.77, max $2.65 (ROI 27.3). 2031: min $1.38, avg $1.95, max $2.99 (ROI 40.3). 2032: min $1.55, avg $2.25, max $3.52 (ROI 61.6). 2033: min $1.75, avg $2.58, max $4.12 (ROI 85.3). 2034: min $1.67, avg $2.51, max $4.08 (ROI 80.4). 2035: min $1.70, avg $2.59, max $4.29 (ROI 86.6).
2040: min $2.25, avg $3.73, max $6.61 (ROI 168.5). 2050: min $3.34, avg $6.39, max $12.50 (ROI 359.8). Overall, the long-run outlook is bullish with meaningful upside by 2050, albeit with considerable uncertainty in the near term.
Tap a question to reveal the answer.
2030 min 1.28, avg 1.77, max 2.65, ROI 27.3, sentiment BULLISH.
2033 max 4.12, 2034 max 4.08, 2035 max 4.29; the forecast does not list $5 as a 2033–2035 peak.
Near term is NEUTRAL (2026–2029), with a shift to BULLISH sentiment in 2030 and beyond. The long-term outlook shows substantial upside by 2050 (avg 6.39, max 12.50; ROI 359.8), but these are estimates, not guarantees.
Current price is $1.39 and market cap is $214.41M.
2050 min 3.34, avg 6.39, max 12.50, ROI 359.8, sentiment BULLISH.
Coherus Oncology, Inc. Community Discussion
0Share your Coherus Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.